CUSIP No. 63009J107
SCHEDULE 13G
Nanobiotix S.A.
ITEM 1(b) | ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES: |
60 Rue de Wattignies, 75012 Paris, France
ITEM 2(a) | NAME OF PERSON FILING: |
This statement is being filed by Johnson & Johnson Innovation-JJDC, Inc., a Delaware corporation (“JJDC”), and Johnson & Johnson, a New Jersey corporation (“J&J”). JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by JJDC and J&J are directly beneficially owned by JJDC. J&J may be deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC. The Joint Filing Agreement between JJDC and J&J is attached hereto as Exhibit A.
ITEM 2(b) | ADDRESS OF PRINCIPAL BUSINESS OFFICE: |
JJDC: 410 George Street, New Brunswick, NJ 08901
J&J: One Johnson & Johnson Plaza, New Brunswick, NJ 08933
JJDC: Delaware
J&J: New Jersey
ITEM 2(d) | TITLE OF CLASS OF SECURITIES: |
Ordinary Shares, €0.03 nominal value per share (“Ordinary Shares”)
63009J107
This CUSIP Number applies to the Issuer’s American Depositary Shares, each representing one Ordinary Share. No CUSIP Number has been assigned to the Ordinary Shares.
4